---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-023059"
form_type: "8-K"
ticker: "ORGO"
cik: "0001661181"
company_name: "Organogenesis Holdings Inc."
filed_at: "2024-02-29T23:59:59+00:00"
generated_at: "2026-06-05T06:50:40.350364+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Organogenesis Q4 revenue $99.7M (-14% YoY); net loss $0.6M; FY2024 guides $445M-$470M

## Summary
- Net revenue Q4 $99.7M (-14% YoY): Advanced Wound Care $93.2M (-14%), Surgical & Sports Medicine $6.5M (-3%).
- Q4 net loss $0.6M vs net income $7.5M; adjusted net income $1.9M vs $8.9M.
- FY2023 net income $4.9M vs $15.5M; adjusted EBITDA $42.6M vs $49.3M.
- FY2024 revenue guidance $445M-$470M (3%-9% growth); net income (loss) range ($10.6M)-$4.6M.
- Management highlights progress on ReNu program for knee osteoarthritis as key value driver.

## SEC filing metadata
- accession: 0000950170-24-023059
- form_type: 8-K
- ticker: ORGO
- cik: 0001661181
- company_name: Organogenesis Holdings Inc.
- filed_at: 2024-02-29T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661181/000095017024023059/0000950170-24-023059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661181/000095017024023059/orgo-20240229.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-023059
- JSON: https://secwatch.observer/filing/0000950170-24-023059.json
- Plain text: https://secwatch.observer/filing/0000950170-24-023059.txt

## Key facts
- Earnings Releases
  Organogenesis Holdings Inc. reported the fourth quarter ended December 31, 2023 results: revenue $99.7 million, net income Net loss of $0.6 million.
  - Period: the fourth quarter ended December 31, 2023
  - Revenue: $99.7 million
  - Net income: Net loss of $0.6 million
  - Result: reported results
  source text: Net revenue of $99.7 million for the fourth quarter of 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1661181/000095017024023059/0000950170-24-023059-index.htm
- Earnings Releases
  Organogenesis Holdings Inc. reported the fiscal year ended December 31, 2023 results: revenue $433.1 million, net income Net income of $4.9 million. Guidance initiated.
  - Period: the fiscal year ended December 31, 2023
  - Revenue: $433.1 million
  - Net income: Net income of $4.9 million
  - Guidance: initiated
  - Result: reported results
  source text: Net revenue of $433.1 million for the year ended December 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1661181/000095017024023059/0000950170-24-023059-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.